731. First Line Therapy for HIV: Standard NNRTI vs. New Alternatives (RAL & MVC)
Session: Interactive Session: Clinical Controversies in Infectious Diseases
Friday, October 21, 2011: 3:35 PM
Room: Grand Ballroom (East-West)


Roy M. Gulick, MD, FIDSA, Weill Cornell Medical College, New York, NY

Dr. Gulick is Professor of Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University in New York City. Dr. Gulick’s research interests include designing, conducting and analyzing clinical trials to refine antiretroviral therapy strategies and assess antiretroviral drugs with new mechanisms of action. He currently serves as Principal Investigator of the Cornell HIV Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG), sponsored by the National Institutes of Health. He also serves as a Board Member of the International AIDS Society-USA, and as a member of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services. He previously served as Chairman of the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) and as Co-Chairman of the Forum for Collaborative HIV Research. He is a member of the American Society of Clinical Investigation, the Infectious Diseases Society of America, and the International AIDS Society and has presented at national and international meetings and published widely in the field of HIV/AIDS.



Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.